Lilly Just Placed Million Bet on Injectables Boom
Lilly is backing Absci with a $40 million investment as Absci advances ABS-201, a next-gen injectable targeting hair ...
Wondering who needs long term care insurance at 55? Learn about the key factors that determine your need for coverage.
27,171 articlesLilly is backing Absci with a $40 million investment as Absci advances ABS-201, a next-gen injectable targeting hair ...
Ford's China negotiations could redefine its growth trajectory. This article explains the real reason investors shoul...
Warner Bros Discovery's 2026 earnings call transcript offers more than quarterly figures. This analysis breaks down t...
Oracle isn't done spending on AI, and the move is shaking up how investors view cloud growth and profitability. This ...
Job seekers face mounting anxiety as hiring slows despite a tight labor market, leaving many worried about fit, pay, ...
Small-cap healthcare stocks are gaining traction in 2026 as trial milestones and funding flow refresh investor intere...
A growing cohort of retirees is quietly collecting income from dividend-rich UK stocks, using low-cost funds that bun...
A new global liveability ranking places a major city at the bottom in 2026, triggering concerns about investment, hou...
A cash-generative biotech near $50 is drawing buyers amid a market shift toward defensible healthcare names. Here’s w...
Stocks retreat as Novo Nordisk and Jefferies face analyst downgrades, while Talkspace advances toward a private-equit...
Barclays boosts its target on Hims & Hers Health as Novo Nordisk deal removes a key legal overhang, while Progyny see...
The beauty health (skin) 2025 landscape is reshaping portfolios. This guide breaks down earnings signals, growth engi...